REG - Venture Life Group - Director/PDMR Shareholding

Venture LifeAnnouncement

02/09/2024 10:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240902:nRSB5324Ca&default-theme=true

RNS Number : 5324C  Venture Life Group PLC  02 September 2024

2 September 2024

 

VENTURE LIFE GROUP PLC

 

("Venture Life", "VLG" or the "Group")

 

Director/PDMR Shareholding

 

Futher to the announcement on 23 August 2023 of the exercise of options by
Jerry Randall (Chief Executive Officer) and Gianluca Braguti (Chief
Manufacturing Officer), the Company announces that both Jerry Randall and
Gianluca Braguti sold ordinary shares of 0.3 pence each in the capital of the
Company ("Ordinary Shares") in order to satisfy personal tax liabilities
resulting from the exercise of the options (the "Share Sale").

Details of the Share Sale and the resultant beneficial interests' in the
Company by both Jerry Randall and Gianluca Braguti are as follows:

 

 Director          Date of sale    Previous shareholding  Ordinary Shares sold  Price per Ordinary Share  Resultant shareholding
 Jerry Randall     29 August 2024  2,309,139*             105,939               45.56 pence               2,203,200 (1.73%)
 Gianluca Braguti  30 August 2024  3,923,055              77,930                46.00 pence               3,845,125 (3.03%)

 

 

For further information, please contact:

 

Venture Life Group PLC
 
                +44 (0) 1344 578004

Jerry Randall, Chief Executive Officer

Daniel Wells, Chief Financial Officer

 

Cavendish Capital Markets Limited (Nomad and
Broker)                                +44 (0)
20 7720 0500

Stephen Keys / Camilla Hume (Corporate Finance)

Michael Johnson (Sales)

 

About Venture Life (www.venture-life.com (http://www.venture-life.com/) )

Venture Life is an international consumer self-care company focused on
developing, manufacturing and commercialising products for the global
self-care market. With operations in the UK, Italy, The Netherlands and
Sweden, the Group's product portfolio includes some key products such as the
UltraDEX and Dentyl oral care product ranges, the Balance Activ range in the
area of women's intimate healthcare, the Lift and Glucogel product ranges for
hypoglycaemia, Gelclair and Pomi-T for oncology support, Earol for ear wax
removal, products for fungal infections and proctology, and dermo-cosmetics
for addressing the signs of ageing. Its products are sold in over 90 countries
worldwide.

The products, which are typically recommended by pharmacists or healthcare
practitioners, are available primarily through pharmacies and grocery
multiples. In the UK and The Netherlands these are supplied direct by the
company to retailers, elsewhere they are supplied by the Group's international
distribution partners.

Through its two Development & Manufacturing operations in Italy and
Sweden, the Group also provides development and manufacturing services to
companies in the medical devices and cosmetic sectors.

 

The Company makes the following disclosures in accordance with article 19(3)
of the Market Abuse Regulation:

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Jerry Randall

 2    Reason for the notification

 a)   Position/status                                              Chief Executive Officer

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Venture Life Group plc

 b)   LEI                                                          213800S8CZUPLAB2KC70

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary Shares of 0.3p each in Venture Life Group plc

      Identification code

                                                                   GB00BFPM8908

 b)   Nature of the transaction                                    Sale of Ordinary Shares

 c)   Price(s) and volume(s)                                       105,939 Ordinary Shares at 45.56 pence per Ordinary Share

 d)   Aggregated information                                       n/a

      - Aggregated volume

      - Price

 e)   Date of the transaction                                      29 August 2024

 f)   Place of the transaction                                     London Stock Exchange

 

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Gianluca Braguti

 2    Reason for the notification

 a)   Position/status                                              Chief Manufacturing Officer

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Venture Life Group plc

 b)   LEI                                                          213800S8CZUPLAB2KC70

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary Shares of 0.3p each in Venture Life Group plc

      Identification code

                                                                   GB00BFPM8908

 b)   Nature of the transaction                                    Sale of Ordinary Shares

 c)   Price(s) and volume(s)                                       77,930 Ordinary Shares at 46.00 pence per Ordinary Share

 d)   Aggregated information                                       n/a

      - Aggregated volume

      - Price

 e)   Date of the transaction                                      30 August 2024

 f)   Place of the transaction                                     London Stock Exchange

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFIFVAAFIFIIS